About This Video
On the latest CSE Issuer Update, Salim Dhanji, Co-Founder and CEO of ME Therapeutics Holdings Inc. (CSE: METX), discusses the company's efforts to develop next-generation cancer therapies that work by re-engineering a patient's immune system directly within the body. The company's immuno-oncology programs are designed to address key barriers that limit the effectiveness of existing cancer treatments, including immune suppression within tumours and the inability of immune cells to recognize cancer cells.
Advancing novel immune engineering technologies toward the clinic.
A recent milestone includes the licensing of a CD22-targeting nanobody from the National Research Council of Canada, which is being incorporated into an in vivo CAR-T platform designed to program immune cells inside the patient’s body. Over the next 12 months, the company plans to expand its research team, advance lead programs toward clinical readiness, and engage with regulators including Health Canada and the FDA.
“We're taking patients and providing a therapy that actually re-engineers their immune cells in the body to either directly recognize their cancer cells or overcome a suppressive tumour environment.” - Salim Dhanji, CEO, ME Therapeutics Holdings Inc.
Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe
STAY CONNECTED WITH THE CSE
=============================
- NEWSLETTER: https://go.thecse.com/CSE-Mailing-List-Subscribe
- PODCAST: https://blog.thecse.com/cse-podcasts/
- INSTAGRAM: https://www.instagram.com/canadianexchange/
- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
- TWITTER: https://twitter.com/CSE_News
- BLOG: https://blog.thecse.com/
- WEBSITE: https://thecse.com/
- MAGAZINE: https://issuu.com/thecse/docs
Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.
My name is Salem Danji. I'm the co-founder and chief executive officer of Mi Therapeutics Holdings Incorporated. listed on the CSSE under the ticker Mex. Mi Therapeutics is at the forefront of a new wave of cancer medicines that work by engineering immune cells in a patient's body. Our programs tackle two of the major roadblocks that prevent immunoncology drugs from working in the majority of patients. those are the suppressive
tumor micro environment and also the lack of pre-existing immune recognition. So our our company was founded by scientists and we're advancing two programs that have the potential to transform cancer treatment over the next year. We're expecting to continue to advance our programs towards a clinical trial. our goal is to have a meeting with Health Canada or the FDA in the next year in advance of a
clinical study for one of our lead programs. The most exciting thing about about MI therapeutics is the fact that we are working in this immune engineering or reprogramming space. So there's been a lot of excitement around this area over the last few years. And basically what we're doing is we're taking patients and we're providing a drug or a therapy that actually re-engineers their immune cells in the
body to either directly recognize their cancer cells or overcomes a suppressive tumor environment which allows a pre-existing immune response to kick off. We recently licensed an exciting asset from the National Research Council of Canada. And this asset is a nanobbody that targets a protein called CD22 which we which is currently in a clinical trial. We're taking that program and we're actually moving it into what we call an invivo chimeriic
antigen receptor program where we're actually engineering a patient's immune cells to recognize that protein directly in the body and those cells then go in and kill all the cancer cells. So a nanobbody is is I don't know if you've heard of antibodies in terms of the immune response. A nanobbody is an antibbody that's produced in llamas or camels. and it's about half the size of a standard
antibbody. So it's it it has a lot of benefits over a standard antibbody technology. Biotech is a very capital intensive business to be honest with you. you know, companies have to transition from, you know, what we call pre-clinical research, which is kind of early stage research in animal models and in dishes. to actually being able to move into human clinical trials. Even the clinical trials require, you
know, multiple phases. So, you have phase one, phase 2, and phase three. And each of them become progressively more expensive. So at the end of the day, what we're looking for are investors who believe in the technology and the story and believe that we have a product that we can move through the different phases of the clinical trials and get to market but also be there to support us all the
way through with you know financially mo for the most part. So in the next year we're planning to continue growing our research team. So we have really exciting programs that target different aspects of the immune system all involving engineering the immune response in a patient using the same technology. we have you know we're working on clinically validated important scientific targets using kind of worldclass delivery technology
from worldclass partners here in Vancouver. and we're hoping to advance one of our lead programs in the next year to a clinical trial. The plan would be to have a meeting with a regulatory agency like Health Canada or the FDA over the next 12 months. To find more information about ME therapeutics, you can go to www.mether therapeutics.com.



